

Special Issue

Multidrug-Resistant Organisms (MDROs) in Solid Organ Transplants and the Use of New Beta-lactam Antibiotics

Message from the Guest Editor

Solid organ transplantation (SOT) has revolutionized the treatment of end-stage organ failure, offering hope and extended life to thousands of patients worldwide.

However, the success of transplantation is threatened by the emergence and spread of multidrug-resistant organisms (MDROs), which can cause increased morbidity and mortality. This Special Issue aims to explore and improve knowledge regarding the efficacy and safety profiles of these new drugs, considering (i) the drug interactions, side effects, and potential complications associated with immunosuppression; (ii) optimal drug combinations; and (iii) the choice of a first-line empiric therapy. The scope of this Special Issue includes, but is not limited to, the following topics:

- Epidemiology of MDROs in SOT;
- Risk factors and outcomes of MDROs in SOT;
- Antibiotic stewardship in the SOT setting;
- Management of Carbapenem-resistant Enterobacteriaceae in SOT;
- Monotherapy and association therapy using new beta-lactamase antibiotics;
- New (other than the last beta-lactamase) therapeutic options against MDROs in SOTs.

Guest Editor

Prof. Dr. Annamaria Cattelan

Infectious and Tropical Diseases Unit, Department of Molecular Medicine, Padua University Hospital, Padua, Italy

Deadline for manuscript submissions

closed (30 April 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/185676

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)